Postoperative Electron Beam Radiotherapy for Keloids: Treatment Outcome and Factors Associated with Occurrence and Recurrence

Sun Young Lee1,3, Jin Park2,3

Departments of 1Radiation Oncology and 2Dermatology, Chonbuk National University Medical School, 3Research Institute of Clinical Medicine Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea

Background: In the treatment of keloids, the recurrence after surgical excision is relatively high. Various types of adjuvant therapy such as radiotherapy and corticosteroid injection have been used to reduce the recurrence. Objective: The aim of this study was to determine the appropriate time for initiating postoperative radiotherapy and to analyze factors associated with the occurrence and recurrence of keloids.

Methods: Of these 37 lesions, 22 were located in the ear lobe, 6 in the helix of the auricle, 4 on the shoulder, 3 on the chest wall, and 2 on the abdomen. Causative factors were piercings (n=24), trauma (n=5), previous surgical lesions or bacillus Calmette-Guerin vaccination lesions (n=3) and acne (n=2). Radiation therapy was initiated within 24 h in 24 lesions, between 24 and 72 h in 6 lesions, and after more than 72 h in 7 lesions. Results: Seven lesions recurred, including 5 recurrences in high stretch-tension regions (p=0.010). Initial treatments were administered within 24 h in 1 lesion and more than 72 h after surgical excision in 6 lesions (p<0.0001). In the 19 patients with family histories, maternal and paternal genetic predispositions were present in 14 and 5 patients, respectively (p=0.033). Conclusion: Radiotherapy should be initiated within 72 h of surgical excision. Location in a high stretch-tension region was significantly associated with recurrence. Patients with a family history showed a significant tendency toward maternal genetic predisposition. Therefore, combination therapy should be considered to reduce the occurrence and recurrence of keloids, and careful observation is required. (Ann Dermatol 27(1) 53~58, 2015)

Keywords: Genetic characteristics, Keloids, Postoperative radiotherapy, Treatment outcome

INTRODUCTION

Keloids are defined as dense fibrous tissue arising from an abnormal healing response to a cutaneous injury that grows beyond the boundaries of the original wound scar1-3. Keloids, which are characterized by a collection of atypical fibroblast with excessive deposition of extracellular matrix components such as collagen, fibronectin, elastin, and proteoglycans, can be considered a “benign neoplasm that does not know when to stop”1. Pathologically, keloids contain relatively acellular centers and thick, abundant collagen bundles that, form nodules in the deep dermal portion of the lesion. Keloids can occur on any part of the body, but they typically, occur on the ear lobes, shoulders, chest, and back2,4. Many unknown factors can cause keloids. However, commonly known causative factors of keloids are piercings, trauma, surgical scars, acne scars, and chickenpox scars1,3. The incidence of keloids is in both sexes, although a female predominance has been reported, most likely due to higher frequency of ear lobe piercings in women2,4. When they occur in the head and neck area, keloids are associated with unpleasant cosmetic consequences, especially in younger patients2,4.
addition to, cosmetic problems, keloid patients can experience itching, redness, and unusual sensations\(^2\). Although they are more likely to develop in people with darker skin, keloids can occur all skin types. The tendency to form keloids sometimes appears to run in families. Notably, the connection between family history and a hereditary tendency for keloid formation has been controversial; some authors have reported that 10% of patients may have a family history, but no specific research on family history has been reported\(^3,4\). Various methods for the treatment of keloids have been attempted, including intralesional steroids, interferon and fluorouracil injections, laser therapy, cryotherapy, silicone gel sheet applications, surgical excision, external radiation therapy, and brachytherapy\(^5,6\). However, these treatments are largely ineffective, and the lesions often return. Moreover, despite the many treatment methods attempted, a satisfactory method has yet to be reported. Many authors have reported on the surgical excision of keloids, which is followed by recurrence in 50%~80% of patients\(^1,7\). Therefore, adjuvant treatment such as radiation therapy has also been considered as a means of improving therapeutic outcomes after surgery\(^1,7,8\).

A variety of radiation techniques such as electron beam radiotherapy, and iridium\(^{-192}\) brachytherapy with implants or strontium\(^{-90}\) dermal plates can be used, and postoperative radiotherapy is a highly effective therapeutic method\(^7,8\). This study aimed to evaluate the results of postoperative electron beam radiotherapy, and to analyze factors associated with keloid occurrence and recurrence.

**MATERIALS AND METHODS**

**Patients**

From January 2006 to January 2012, 30 patients with 37 keloid lesions were treated with postoperative electron beam radiotherapy. There were 23 female patients (29 lesions) and 7 male patients (8 lesions) with ages ranging from 11 to 66 year (mean, 23.9 years). Sites of keloid development included the ear lobe (n=22, 59.5%), the helix of the auricle (n=6, 16.2%), the shoulder (n=4, 10.8%), the chest wall (n=3, 8.1%) and the abdomen (n=2, 5.4%). All lesions were surgically excised, and the clinical diagnosis of keloids was confirmed histopathologically. Wide local excision was performed for 21 lesions, and core excision was performed for 16 lesions. Factors contributing to keloid formation included piercing (24 lesions; 64.9%), trauma (5 lesions; 13.5%), surgical scars (3 lesions; 8.1%), bacillus Calmette-Guerin vaccination scars (3 lesions; 8.1%), and acne (2 lesions; 5.4%). A total of 19 patients (22 lesions) had a family history. Among these, maternal and paternal hereditary tendencies were present in 14 patients (16 lesions, 73.7%), and 5 patients (6 lesions, 26.3%), respectively. Because more than 50% of keloid recurrences occur within 6 months of treatment\(^1,5,7\), a follow-up period of at least 6 months was necessary and we observed the treated lesions every 3 months after radiotherapy. The median follow-up period was 27.4 months (range, 9~51 months) (Table 1). Our study protocol was approved by the institutional review board of Chonbuk National University Hospital (CUH 2012-02-003-001).

**Radiation treatment**

Radiation therapy was applied with a 6-MeV electron beam. To ensure an adequate radiation dose was applied to the surface of the skin, a 0.5 or 1-cm thick silicone bolus such as a tissue compensator was placed on the keloid surgical scar, based on the characteristics of the scar. The electron beam irradiated the normal skin area 0.5 or 1 cm from the margin of the operative suture lines. The surrounding normal tissue was shielded with lead (equivalent to 6 mm of Pb). The total treatment doses administered

| Characteristic       | Number of lesion sites (n=37) | Percentage |
|----------------------|------------------------------|------------|
| Age (y)              |                              |            |
| Range                | 11~66                        |            |
| Mean                 | 23.8                         |            |
| Sex                  |                              |            |
| Male                 | 8 (7)                        | 21.6       |
| Female               | 29 (23)                      | 78.4       |
| Site of lesions      |                              |            |
| Ear lobe             | 22                           | 59.5       |
| Helix of auricle     | 6                            | 16.2       |
| Shoulder             | 4                            | 10.8       |
| Chest wall           | 3                            | 8.1        |
| Abdomen              | 2                            | 5.4        |
| Causative factors    |                              |            |
| Piercing             | 24                           | 64.9       |
| Trauma               | 5                            | 13.5       |
| Surgical scar        | 3                            | 8.1        |
| Bacillus Calmette-Guerin vaccination scar | 3 | 8.1 |
| Acne                 | 2                            | 5.4        |
| Family history       |                              |            |
| Positive             | 22 (19)                      | 59.5       |
| Maternal hereditary tendency | 16 (14) | 71.4 |
| Paternal hereditary tendency | 6 (5) | 28.6 |
| Negative             | 15 (11)                      | 40.5       |

Values are presented as the numbers of scar sites (the numbers of patients).
ranged from 12 to 18 Gy: 12 Gy (biological effective dose [BED] 15.6 Gy) for 11 lesions, 15 Gy (BED 19.5 Gy) for 20 lesions, 16 Gy (BED 22.4 Gy) for 3 lesions, and 18 Gy (BED 23.4 Gy) for 3 lesions. The treatment dose distribution by site was as follows: 12 Gy for 9 lesions in the ear lobe and 2 lesions in the helix of the auricle; 15 Gy for 13 lesions in the ear lobe, 4 lesions in the helix of the auricle, 2 lesions in the chest wall, and 1 lesion in the shoulder; 16 Gy for 1 lesion in the chest wall, 1 lesion in the shoulder, and 1 lesion in the abdomen; 18 Gy for 2 lesions in the shoulder and 1 lesion in the abdomen. Radiation therapy was administered every other day at 3 or 4 Gy. Radiation therapy was initiated within 24 h for 24 lesions, between 24 and 72 h for 6 lesions, and more than 72 h after surgical excision for 7 lesions (Table 2).

**Statistical analysis**

The treatment outcome as well as factors associated with occurrence and recurrence were analyzed using the chi-square test (Fisher’s exact test) with a p-value significance level using SAS version (SAS Institute, Cary, NC, USA) 9.2 ($p < 0.05$).

**RESULTS**

In this study, the recurrence-free success rate was 81.1% during the follow-up period (Fig. 1). In our cohort of 30 keloid patients with 37 lesions who received postoperative radiation therapy, 7 lesions recurred (Fig. 2). The median to recurrence was 7.9 months ($6 \sim 13$ months).

Of the 7 lesions, 4 recurred in male patients and 3 recurred in female patients. Areas of recurrence were the ear lobe (1 lesion), the helix of the auricle (1 lesion), the shoulder (2 lesions), the chest wall (2 lesions), and the abdomen (1 lesion). The radiation doses administered to the 7 recurred lesions were 12 Gy (2 lesions), 15 Gy (2 lesions), 16 Gy (1 lesion), and 18 Gy (2 lesions). The timing of radiation treatment after surgical keloid removal was within 24 h for 1 lesion, and after more than 72 h for 6 lesions ($p < 0.0001$).

Five of the 7 recurred lesions appeared in high stretch-tension regions including the shoulder, chest wall, and abdomen while the remaining 2 lesions appeared in low stretch-tension regions including the ear lobe and helix of the auricle ($p = 0.010$) (Table 3). Sex, causative factors, age, family history, surgical methods,
Fig. 2. (A) A lesion was observed on the left ear lobe. (B) Radiotherapy was performed 7 days after surgery. A small, recurrent, hypervascular lesion re-grew after radiotherapy. Steroid injection therapy was administered to the recurrent lesion.

Table 3. Characteristics of 7 recurrent lesions in the keloids patients after postoperative radiation therapy

| Characteristic          | Number of recurrent lesion sites (n=7) | p-value * |
|-------------------------|----------------------------------------|-----------|
| Sex                     |                                        |           |
| Male                    | 4                                      |           |
| Female                  | 3                                      |           |
| Recurrent area          |                                        |           |
| Ear lobe                | 1                                      |           |
| Helix of auricle        | 1                                      |           |
| Shoulder                | 2                                      |           |
| Chest wall              | 2                                      |           |
| Abdomen                 | 1                                      |           |
| Radiation dose          |                                        |           |
| 12 Gy                   | 2                                      |           |
| 15 Gy                   | 2                                      |           |
| 16 Gy                   | 1                                      |           |
| 18 Gy                   | 2                                      |           |
| The initial time of radiation treatment after surgical removal | <0.0001 |           |
| Within 24 h             | 1                                      |           |
| 24~72 h                 | 0                                      |           |
| More than 72 h          | 6                                      |           |
| Stretch tension-region  |                                        | 0.010     |
| High*                   | 5                                      |           |
| Low†                    | 2                                      |           |

*High stretch-tension areas were on the shoulder, chest wall, and abdomen. †Low stretch-tension areas were on the ear lobe and helix of auricle. *Chi-square test (Fisher’s exact test): recurrent rate after postoperative radiation therapy.

Table 4. Analysis of family history and genetic predisposition in 30 keloid patients with 37 lesions

| Variable                        | Number of patients (n=30) | p-value |
|---------------------------------|---------------------------|---------|
| Family history                  |                           | 0.250   |
| Positive                        | 19 (22)                   |         |
| Maternal genetic predisposition | 14 (16)                   | 0.033   |
| Paternal genetic predisposition | 5 (6)                     |         |
| Negative                        | 11 (15)                   |         |
| Recurrence                      |                           | 0.677   |
| Yes                             | 7 (7)                     |         |
| Positive family history         | 5 (5)                     |         |
| Negative family history         | 2 (2)                     |         |
| No                              | 23 (30)                   |         |
| Positive family history         | 14 (17)                   |         |
| Negative family history         | 9 (13)                    |         |

Values are presented as the numbers of patients (the numbers of lesion sites).

and total treatment dose were not associated with keloid recurrence to a statistically significant degree.

Of the 30 patients (37 lesions), 19 (22 lesions) had a family history ($p=0.250$). Among these maternal and paternal hereditary tendencies were observed in 14 (16 lesions) and 5 (6 lesions) patients, respectively ($p=0.033$). In the overall 30 patient cohort, family history was positive in 5 of the 7 patients who developed a recurrence and 14 of the 23 patients who did not ($p=0.677$) (Table 4). Sex, causative factors, lesion location, and age were not statistically associated with keloid development.
During treatment, mild skin erythema (grade 1 dermatitis) was observed in 8 lesions (1 lesion in the ear, 1 lesion in the helix of the auricle lesion, 2 lesions in the chest wall, 2 lesions in the shoulder, 2 lesions in the abdomen), and these symptoms disappeared within a few weeks of treatment. Surgical wounds dehiscence did not occur. During the follow-up period, transient hyperpigmentation was observed in 3 treated lesions (1 lesion in the shoulder, 2 lesions in the abdomen) and the symptoms disappeared within 4 months of treatment. Secondary carcinogenesis did not occur during the follow-up period.

DISCUSSION

Keloids result from defective negative feedback mechanisms in fibroblasts during the wound healing process. They occur outside excessive collagen depositions and are diseases owing to the decomposition of matrix metalloproteinases\textsuperscript{1,9,10}. Keloid occur in contrast to the normal wound healing process, which regulates cell growth and proliferation via changes in cellular signals: keloids have also been known to occur during the wound healing process\textsuperscript{1,3,11}. Compared to normal fibroblasts, keloid-derived fibroblasts are immature and exhibit increased production of type I or III collagen and matrix metalloproteinases. The result is an overgrowth of type III collagen at the wound site, which is then slowly replaced by type I collagen, unlike the normal wound healing process\textsuperscript{1,3,11}. The abnormal expression of various growth factors and related receptors has been associated with keloid-derived fibroblasts\textsuperscript{12,13}. In recent studies, keloid-derived fibroblasts have been shown to overexpress the following growth factors: vascular endothelial growth factor, transforming growth factor (TGF)-beta 1, TGF-beta 2, connective tissue growth factor, the platelet-derived growth factor receptor. In particular, TGF-beta 1, a cytokine that participates in wound healing and fibrosis, is an important component in the formation of keloids and in histamine, which is considered capable of accelerating collagen formation during the proliferation phase of wound healing\textsuperscript{1,3,4,12,13}. Postoperative radiotherapy is expected to favorably impact wound healing in patients with keloids at a time when the connective tissue is more radiosensitive by decreasing fibroblast proliferation and causing a rapid degranulation of mast cells the main secretors of histamine\textsuperscript{5,14,15}. Radiation suppresses collagen synthesis in keloids or hypertrophic scars. This is mediated by the inhibition of TGF-beta 1 release from fibroblasts. Otherwise, histamine released from mast cells stimulates the proliferation of fibroblasts. Radiation inhibits histamine release from mast cells, which in turn inhibits the proliferation of fibroblasts. Thus, the mechanism by which radiation inhibits keloids or hypertrophic scars is the suppression of fibroblast proliferation and inhibition of collagen synthesis\textsuperscript{14,16}.

Considering that the proliferation phase occurs 2 or 3 days (48~72 h) after an injury, radiation therapy should be initiated within 72 h after keloid surgery. In this study, initial radiation treatment occurred more than 72 h after surgery in 6 of the 7 recurring lesions ($p < 0.0001$). Several authors\textsuperscript{14,15} have reported the excessive proliferation of collagen fibers in keloid scars with high stretch-tension. Repeated hyperextension stimulation has been performed on collagen overgrowth at treated keloid sites\textsuperscript{14,15}. Bischof et al.\textsuperscript{15} reported recurrences at sites of high stretch-tension, and these were relatively common. In this study, 5 of the 7 recurring lesions appeared in high stretch-tension regions (the shoulder, chest wall and abdomen) and the remaining 2 lesions appeared in low stretch-tension regions (the ear lobe and helix of the auricle). This difference was statistically significant ($p = 0.010$). Keloid occurrence and recurrence as well as the presence of a family history have been examined in numerous studies within contradictory results. Some authors have reported that both the occurrence and recurrence of keloids is associated with family history, while others reported that family history is not significantly related to keloids. In our study, 19 of the 30 keloid patients who received postoperative radiation therapy had family histories and 11 patients did not ($p = 0.250$). Family history was present in 5 of the 7 patients who displayed recurrence and in 14 of the 23 patients who did not. This difference was not statistically significant ($p = 0.677$). However, in a detailed analysis of genetic predisposition among those with family histories, a maternal inherited genetic predisposition was significantly related to the occurrence of keloids ($p = 0.033$). During fetal development, actin, fibronectin, and ribosomes are known to be inherited mainly from the mother\textsuperscript{17}, and these genetic factors have been associated with keloid development in laboratory micro-array findings from several studies\textsuperscript{17,18}. Satish et al.\textsuperscript{19} reported micro-array data comparing the gene expression profiles of keloid and normal tissues. They found increased expression levels of fibronectin, several actin isoforms, and the alpha-1 chain of type I collagen proteins, which were all associated with abnormal wound healing\textsuperscript{20}. In addition, some tumor-related genes were found to be up-regulated in keloid-derived fibroblasts, with greater increases observed for ribosomal protein 18, an important protein for cell growth, and Stat-3, another oncogene involved in cell proliferation\textsuperscript{19,21}. These in vitro findings, concerning the extracellular matrix and several genes that interact with the complex process of wound healing in general
cannot explain the exact genetic relationship but factors related to the link with maternal genetics were observed. The recurrence rate in our study was 18.9%. The acute side effect of radiation dermatitis was observed in 21.6% of the cases, and chronic side effects were observed in 8.2% of the cases. However, all side effects disappeared during the follow up period. Recurrence rates between 15% and 32.7% have been reported in other studies. Kovalic and Perez monitored 75 patients with 113 treated scars and found an overall local control rate of 73%. Meanwhile, Borok et al. reported excellent cosmetic results without recurrence in 92% of cases. The results of our study can be considered satisfactory in comparison to those of other studies.

Postoperative electron beam radiotherapy can be regarded as an effective treatment method for the prevention of keloid recurrence without serious adverse events. However, radiation therapy should be initiated within 72 h after surgical excision to prevent recurrence. Recurred lesions were more common in high stretch-tension regions than in low stretch-tensions, and this difference was statistically significant. The occurrence of keloids was associated with family history, but this was not statistically significant. However, a significant tendency towards maternal genetic predisposition was observed. Combination therapy with anti-collagen synthesis drugs or silicone sheets should be considered for high stretch-tension areas to reduce stretch tension and inhibit collagen synthesis. Moreover, careful monitoring is necessary in patients with maternal genetic predispositions for keloids.

REFERENCES

1. Marneros AG, Krieg T. Keloids–clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges 2004; 2:905-913.
2. Brisset AE, Sherris DA. Scar contractures, hypertrophic scars, and keloids. Facial Plast Surg 2001;17:263-272.
3. Lee JY, Yang CC, Chao SC, Wong TW. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol 2004;26:379-384.
4. Jung JY, Roh MR, Kwon YS, Chung KY. Surgery and perioperative intralasional corticosteroid injection for treating earlobe keloids: a korean experience. Ann Dermatol 2009; 21:221-225.
5. Clark JA, Turner ML, Howard L, Stanescu H, Kleta R, Kopp JB. Description of familial keloids in five pedigrees: evidence for autosomal dominant inheritance and phenotypic heterogeneity. BMC Dermatol 2009;9:8.
6. Omo-Dare P. Genetic studies on keloid. J Natl Med Assoc 1975;67:428-432.
7. Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg 2003;111: 547-553; discussion 554-555.
8. van de Kar AL, Keulen M, van Zijljen PP, Oldenburger F. The results of surgical excision and adjuvant irradiation for therapy-resistant keloids: a prospective clinical outcome study. Plast Reconstr Surg 2007;119:2248-2254.
9. Midwood KS, Williams LV, Schwarzauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 2004;36:1031-1037.
10. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
11. Santoro MM, Gaudino G. Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp Cell Res 2005;304:274-286.
12. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br J Dermatol 2005;153:295-300.
13. Topol BM, Lewis VL Jr, Benveniste K. The use of antihistamine to retard the growth of fibroblasts derived from human skin, scar, and keloid. Plast Reconstr Surg 1981;68:227-232.
14. Caccialanza M, Piccinno R, Schiera A. Postoperative radiotherapy of keloids: a twenty-year experience. Eur J Dermatol 2002;12:58-62.
15. Bischof M, Krempien R, Debus J, Treiber M. Postoperative electron beam radiotherapy for keloids: objective findings and patient satisfaction in self-assessment. Int J Dermatol 2007;46:971-975.
16. Rosen EM, Goldberg ID, Myrick KV, Levenson S. Radiation survival properties of cultured vascular smooth muscle cells. Radiat Res 1984;100:182-191.
17. Kingston HM. Genetics assessment and pedigree analysis. In: Rimoin DL, Connor JM, editors. Emery and Rimoin’s principles and practice of medical genetics. 5th ed. Philadelphia: Churchill Livingstone, 2007:518-535.
18. Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol 2001; 137:1429-1434.
19. Satish L, Lyons-Weiler J, Hebda PA, Wells A. Gene expression patterns in isolated keloid fibroblasts. Wound Repair Regen 2006;14:463-470.
20. Lim CP, Phan TT, Lim JJ, Cao X. Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene 2006;25:5416-5425.
21. Bayat A, Bock O, Mrowietz U, Ollier WE, Ferguson MW. Genetic susceptibility to keloid disease and transforming growth factor beta 2 polymorphisms. Br J Plast Surg 2002; 55:283-286.
22. Kovalic JJ, Perez CA. Radiation therapy following keloidectomy: a 20-year experience. Int J Radiat Oncol Biol Phys 1989;17:77-80.
23. Borok TL, Bray M, Sinclair I, Plaajar J, LaBirth L, Rollins C. Role of ionizing irradiation for 393 keloids. Int J Radiat Oncol Biol Phys 1988;15:865-870.